These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling.

Drug Details

Company Name	Business Partner	Drug Name	Generic Name	Unique ID	Studied Indications or Disease	Phase
Abbott Laboratories		Humira	Adalimumab	M02-570	Psoriatic Arthritis	Phase III

Clinical Study Summary

Protocol No. M02-570: A Phase III Multicenter Study of the Safety and Efficacy of Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Moderate to Severely Active Psoriatic Arthritis (PsA) Subjects with Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy